Osong Public Health Res Perspect.
2018 Jun;9(3):133-139. 10.24171/j.phrp.2018.9.3.10.
The 2nd Meeting of National Control Laboratories for Vaccines and Biologicals in the Western Pacific
- Affiliations
-
- 1National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju, Korea. 0jjy@korea.kr
- 2World Health Organization, Regional Office for the Western Pacific, Manila, Philippines.
- 3National Institute of Infectious Diseases, Tokyo, Japan.
- 4Haemostasis Section, Biotherapeutics Group, National Institute for Biological Standards and Control, Potters Bar, United Kingdom.
- 5Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, Canada.
- 6Korea Hemophilia Foundation, Seoul, Korea.
- 7Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
- 8National Institutes for Food and Drug Control, China Food and Drug Administration, Beijing, China.
- 9National Institute for Control of Vaccines and Biologicals, Ministry of Health Viet Nam, Hanoi, Viet Nam.
- KMID: 2416897
- DOI: http://doi.org/10.24171/j.phrp.2018.9.3.10
Abstract
- The Second Meeting of the National Control Laboratories for Vaccines and Biologicals in the Western Pacific, was jointly organized by the National Institute of Food and Drug Safety Evaluation of the Ministry of Food and Drug Safety in the Republic of Korea, and by the World Health Organization Regional Office for the Western Pacific. In the National Lot Release Systems session countries including Canada, China, Japan, Malaysia, Vietnam, and the Republic of Korea, all shared information on their current Lot Release Systems, including current practices and developments in risk-based official lot release of vaccines. In the session on Quality Control of Blood Products, experts from the National Institute for Biological Standards and Control shared quality control and research results for; blood coagulation factor VIII products, and the measurement of procoagulant activity in immunoglobulin products. Representatives from Japan proposed a regional collaborative study to test aggregated immunoglobulin free from complement activity. A cell-based Japanese encephalitis vaccine potency assay was proposed by representatives from Korea and they also called for voluntary participation of other National Control Laboratories in a collaborative study, on the first Korean Gloydius anti-venom standard. Participants agreed in general to continue communicating, and coordinate presentation of the study results.
MeSH Terms
-
Blood Coagulation Factors
Canada
China
Complement System Proteins
Encephalitis, Japanese
Factor VIII
Immunoglobulins
Japan
Korea
Malaysia
Quality Control
Republic of Korea
Vaccine Potency
Vaccines*
Vietnam
World Health Organization
Blood Coagulation Factors
Complement System Proteins
Factor VIII
Immunoglobulins
Vaccines
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The First Meeting of the National Control Laboratories for Vaccines and Biologicals in the Western Pacific in 2016
- WHO Western Pacific Regional Action Plan for the Prevention and Control of NCDs (2014-2020)
- WHO’s Initiatives to Control Vaccine Preventable Diseases (VPD) and Labnet for Targeted VPDs in the Western Pacific Region
- A two-year progress report on medical education standards in the Western Pacific: Presidential address 2018
- 2004 IPA Asia Pacific Regional Meeting
